Addendum
Ivacaftor (cystic fibrosis, 6 years and older, with G551D mutation) - Addendum to Commission A19-65
Report documents
-
Addendum
Ivacaftor (cystic fibrosis, 6 years and older, with G551D mutation) - Addendum to Commission A19-65
Dossier assessment
Indication:
Cystic fibrosis (CF) in patients aged 6 years and older and weighing 25 kg or more who have a G551D mutation in the CFTR gene
Result of dossier assessment:
Conclusion of dossier assessment A19-65 unchanged
Additional information
Federal Joint Committee (G-BA)
2020-02-20 A G-BA decision was published.
Project details
- Project no.
- A20-04
- Commission
- Commission awarded on 07.01.2020 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Ivacaftor (cystic fibrosis, 6 years and older, with G551D mutation) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed